Wayrilz (Rezabrutinib) is a novel kinase inhibitor, first approved for marketing in the United States in 2025. As a small-molecule covalent reversible inhibitor targeting Bruton's Tyrosine Kinase (BTK), this medication provides a new treatment option for patients with immune thrombocytopenia (ITP).
Indications for Wayrilz (Rezabrutinib)
Primary Therapeutic Areas
Wayrilz is indicated for the treatment of persistent or chronic immune thrombocytopenia in adults.
Immune thrombocytopenia is an autoimmune disease characterized by increased platelet destruction and insufficient platelet production, leading to elevated bleeding risk.
This medication is specifically targeted at patient populations with inadequate response to previous treatments, offering a new therapeutic choice for patients who do not respond to conventional therapies.
Usage Limitations
The efficacy in pediatric patients has not been established.
Use should be avoided in patients with moderate to severe hepatic impairment.
Use should be avoided in patients with severe renal impairment.
Specifications and Properties of Wayrilz (Rezabrutinib)
Dosage Specifications
Wayrilz is available in a standard specification of 400 mg film-coated tablets.
Each tablet contains 400 mg of active ingredient (rezabrutinib), designed in an orange, capsule-like shape, with the letter "P" engraved on one side and the marking "400" on the other side.
Drug Composition
Active ingredient: Rezabrutinib, a white to off-white solid.
Excipients (core): Crospovidone (Type A), microcrystalline cellulose, sodium stearyl fumarate.
Excipients (coating): FD&C Yellow No. 6/Sunset Yellow FCF Aluminum Lake, polyethylene glycol, partially hydrolyzed polyvinyl alcohol, talc, titanium dioxide.
Physicochemical Properties
The chemical name of rezabrutinib is 1-piperidinepropionitrile, with a molecular formula of C₃₆H₄₀FN₉O₃ and a molecular weight of 665.77 Daltons.
This substance is freely soluble in ethanol, slightly soluble in isopropyl alcohol, and practically insoluble in water.
Storage Methods for Wayrilz (Rezabrutinib)
Storage Condition Requirements
Wayrilz should be stored at room temperature, specifically between 20°C and 25°C (68°F and 77°F), with short-term storage allowed within the range of 15°C to 30°C (59°F to 86°F).
Packaging Protection Measures
The medication must be stored in its original packaging.
Protect from light: Prevent direct exposure to light.
Moisture protection: Avoid humid environments.
Sealed storage: Ensure the packaging is intact.
Handling Precautions
Always keep the medication in its original moisture-proof packaging.
Remove from the aluminum foil blister only before the first use.
Keep out of the reach of children to ensure safe storage of the medication.
